Compare LyondellBasell Industries NV (LYB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs TransMedics Group Inc — how do they compare? LyondellBasell Industries NV trades at $63.24 (market cap $20.67B), while TransMedics Group Inc trades at $87.46 (market cap $3.10B). The key difference: LyondellBasell Industries NV is far larger — about 6.7× TransMedics Group Inc's market cap, and LyondellBasell Industries NV pays a 6.44% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| LYB | TMDX | |
|---|---|---|
Market Cap | $20.67B | $3.10B |
Sector | Basic Materials | Technology |
52-Week High | $82.38 | $150.42 |
52-Week Low | $42.28 | $61.99 |
Enterprise Value | $32.26B | $3.49B |
Dividend Yield | 6.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell Industries (LYB) trades at $62.65, up 5.13% today, reflecting positive momentum following a strong Q2 2026 earnings beat. The stock shows bullish technical signals with moving averages supporting an uptrend, while fundamentals reveal a mixed picture with declining revenue but improving quarterly EPS. Recent news highlights supply disruptions supporting margins and analyst upgrades after the earnings report.
The outlook is cautiously optimistic with a consensus price target of $70.56, suggesting upside potential. Key opportunities include operational leverage from cost cuts and favorable petrochemical supply dynamics, but risks persist from volatile commodity markets and negative net income margins. Institutional sentiment leans positive with recent stake increases.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
